Delving into the Latest Updates on PBF-680 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

PBF 680

Target

A1R

Mechanism

A1R antagonists(Adenosine A1 receptor antagonists)

Therapeutic Areas

Respiratory Diseases

Active Indication

Pulmonary Disease, Chronic Obstructive

Inactive Indication

Allergic asthmaLate onset asthma

Originator Organization

Palobiofarma SL

Active Organization

Palobiofarma SL

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

The purpose of the study is to investigate the effect of PBF-680 on the chronic inflammation and the lung function of patients with COPD on top of the standard medication. The effects of PBF-680 administration will also be examined with regards to symptom improvement and safety measures.One oral dose of PBF-680 or placebo will be administered daily for 4 weeks after randomization. The treatments will be administered double-blind with the Investigator and patient unaware of the treatment identity. A total of 102 COPD patients, either male or female, aged 40 to 80 years (inclusive) will be randomized.

Start Date20 Dec 2021

Sponsor / Collaborator

Palobiofarma SL

[+1]

EUCTR2021-001732-25-ES / Unknown statusPhase 2

A phase IIa, randomized, double blind, placebo-controlled study to assess the effect of PBF-680 in patients with moderate to severe COPD on top of standard medication.

Start Date13 Aug 2021

Sponsor / Collaborator-

NCT03774290 / CompletedPhase 2

A Phase II, Double-blind, Randomized, Parallel-group, Placebo- Controlled Multi-center Study to Investigate the Effect of the Adenosine A1 Receptor Antagonist PBF-680 on Forced Expiratory Volume in 1 Second (FEV1) in Patients With Mild-to-moderate Persistent Atopic Asthma

The present trial is an exploratory study aiming at evaluating the safety, tolerability, and efficacy of a 15-day, once daily administration of 10 mg PBF-680 in subjects with persistent, mild-to-moderate atopic asthma.

Start Date01 Jun 2018

Sponsor / Collaborator

Palobiofarma SL

[+1]

100 Clinical Results associated with PBF-680

Login to view more data

100 Translational Medicine associated with PBF-680

Login to view more data

100 Patents (Medical) associated with PBF-680

Login to view more data

100 Deals associated with PBF-680

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pulmonary Disease, Chronic Obstructive	Phase 2	ES	Palobiofarma SL	20 Dec 2021
Allergic asthma	Phase 2	ES	Palobiofarma SL	01 Jun 2018
Late onset asthma	Phase 2	ES	Palobiofarma SL	01 Apr 2016

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


PBF-680 (ERS2020)	Phase 2	Moderate asthma AMP AHR	18	PBF-680 5 mg	qaarvmgwat(yryvbjssuz) = ysmvrgcbch bwrtbwlmck (dfxrhdmyab, 42.21)	Positive	07 Sep 2020
				PBF-680 20 mg	qaarvmgwat(yryvbjssuz) = wmgulfvuzo bwrtbwlmck (dfxrhdmyab, 39.62) View more
PBF-680 (ERS2020)	Phase 2	Asthma FeNO \| blood eosinophils	8	PBF-680 10mg	jmodzfntzn(bfoglcwjzx) = tiviepafvn ybvydguyhf (wsgcmjhhlu ) View more	Positive	07 Sep 2020
				Placebo	jmodzfntzn(bfoglcwjzx) = cpunufiirk ybvydguyhf (wsgcmjhhlu ) View more